title: Intravenous immunoglobulins-induced eczematous eruption: a long-term follow-up study.
abstract: BACKGROUND
  High-dose intravenous immunoglobulins have emerged as an important therapy for various diseases. Vesicular eczematous eruption has recently been described as an intravenous immunoglobulins adverse effect. Little is known about patients' characteristics, administration regimens and long-term outcomes.
  
  
  METHODS
  We retrospectively examined a series of 9 patients which had been notified to the Regional Pharmacovigilance Center for an eczematous skin reaction after intravenous immunoglobulins infusion.
  
  
  RESULTS
  There were 8 men and 1 woman. Mean age was 56.4 years. Seven patients were treated with intravenous immunoglobulins for neurological disease. Eruption was mostly localized to palms and soles. All patients improved, either spontaneously or with systemic or topical steroid treatment. Rash recurred in 4 out of 5 patients in which immunoglobulins were readministered. Eruption did not relapse in 3 patients when immunoglobulins preparation was switched for another one.
  
  
  CONCLUSIONS
  Eczematous eruption due to infusion of immunoglobulins is rare although mostly benign side effect. Treatment withdrawal is usually not required if there is a major clinical benefit. Switching the type of IVIg is often a useful strategy.
authors.affiliation: Service de Pharmacologie et Centre Régional de Pharmacovigilance, AP-HP, Hôpital Pitié-Salpétrière, Paris, France. fleuraubart@yahoo.fr
authors.forename: F
authors.initials: F
authors.lastname: Cohen Aubart
authors.forename: S
authors.initials: S
authors.lastname: Barete
authors.forename: Z
authors.initials: Z
authors.lastname: Amoura
authors.forename: C
authors.initials: C
authors.lastname: Francès
authors.forename: Olivier
authors.initials: O
authors.lastname: Lyon-Caen
authors.forename: B
authors.initials: B
authors.lastname: Lebrun-Vignes
mesh_terms: D000328:Adult; D000368:Aged; D001706:Biopsy; D016208:Databases, Factual; D004485:Eczema / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use
chemical_list: D016756:Immunoglobulins, Intravenous; D013256:Steroids